Sökresultat

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/impact/canfaster/canfaster-publications - 2026-08-21

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2026-08-21

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2026-08-21

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2026-08-21

 Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden

https://www.createhealth.lth.se/contact - 2026-08-21

CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our vision: To accelerate translation of breakthrough therapies and diagnostics into clinical practice, improving outcomes for today´s cancer patients while building

https://www.createhealth.lth.se/about - 2026-08-21

Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific clinical needs identified by our clinical partners, leveraging novel technological approaches to accelerate implementation into the clinic with dramatically reduced

https://www.createhealth.lth.se/research - 2026-08-21

Lund University research projects Currently at Lund Univeristy, ten research projects are driven by ten Principle Investigators from the Faculty of Engineering (LTH) and the Faculty of Medicine. The common goal of all of them is to deepen knowledge and fast forward innovations in cancer diagnostics and treatment. Molecular characterisation of breast cancer: biomarkers of risk, prognosis and treatm

https://www.createhealth.lth.se/research/research-projects - 2026-08-21

 Please wait...

https://www.createhealth.lth.se/contact/principal-investigators - 2026-08-21

In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge programme.Other previous and current funding for the CR

https://www.createhealth.lth.se/about/funding - 2026-08-21

L2CancerBridge is a groundbreaking collaborative cancer research programme that bridges two of Europe's leading research institutions: CREATE Health at Lund University, Sweden, and the Swiss Cancer Centre at EPFL in Lausanne, Switzerland. The L2CancerBridge programme exemplifies how international partnerships can accelerate cancer research breakthroughs. By combining the expertise and resources of

https://www.createhealth.lth.se/research/l2cancerbridge-programme-collaborative-excellence - 2026-08-21

 Please wait...

https://www.createhealth.lth.se/contact/antibody-unit - 2026-08-21

Antibody Initiative Advances in antibody engineering have revolutionised cancer therapy, and biological drugs now constitute a cornerstone of frontline treatment across most cancer subtypes. We drive continued innovation and clinical success by continuously enhancing local capabilities in Lund to develop tailored molecules for targeted cancer treatment- specific antigens, immune checkpoints, or as

https://www.createhealth.lth.se/research/technologies - 2026-08-21

Masterprogram, 120 hp Tillämpad klimatstrategi är ett tvärvetenskapligt, tvåårigt masterprogram för dig som har en kandidatexamen inom valfritt ämne. Utbildningen passar speciellt bra för dig som vill arbeta med samhällsplanering och klimatfrågor på lokal, regional eller nationell nivå, eller som vill forska. Masterutbildningen i klimatstrategi är den första och enda i sitt slag i Sverige. Läs mer

https://www.mgeo.lu.se/utbildning/utbildningar-i-miljovetenskap/master-och-magisterprogram-i-miljovetenskap/tillampad-klimatstrategi - 2026-08-21

This page provides information about health promotion benefits at Lund University. Health promotion reimbursement in 2026 From 1 January 2026, reimbursement for health promotion is SEK 3,000 per year. The deadline for applying is 30 November 2026.Purchases of health promotion acitivities made in November and December 2025 can also be reimbursed from the 2026 wellness allowance (up to SEK 3,000). A

https://www.staff.lu.se/employment/work-environment-and-health/health-and-wellness/health-promotion-reimbursement - 2026-08-21

Here you can read more about occupational injury insurance. Content on this page:Occupational injury insuranceCompensation for occupational injuriesWhen you work remotelyOccupational injury insuranceIf you are injured in the workplaceare injured on your way to or from worksuffer from an occupational diseaseyou may be entitled to compensation.If you suffer an occupational injury, you – together wit

https://www.staff.lu.se/employment/insurance/occupational-injury-insurance - 2026-08-21

This page provides information about insurance solutions for research subjects and test persons participating in the activities at Lund University. For persons participating as test subjects in research at Lund University, the Kammarkollegiet's collective insurance policies Insurance for Foreign Visitors and Special Personal Injury Protection (SPS) do not apply. Instead, the department/equivalent

https://www.staff.lu.se/employment/insurance/insurance-research-subjects-and-test-subjects - 2026-08-21

Here employees can find advice on what to do if they are subjected to abusive conduct. Lund University does not accept victimisation or harassment. Content on this page:This constitutes victimisation and harassmentHarassmentDefinition of harassment and sexual harassmentIf something happens – what can you do?Protection against reprisalsIf you are a colleagueSupport and helpFurther reading: How the

https://www.staff.lu.se/employment/work-environment-and-health/your-work-environment/victimisation-and-harassment - 2026-08-21

On this page you will find information about how the work with LUCRIS is organized. Structure LUCRIS is managed according to Lund University's system management model. A central management group, called "LUCRIS förvaltning" oversees the system. There are also several working groups, made up of faculty representatives, that address important issues related to how LUCRIS is used and developed.Each f

https://www.staff.lu.se/research-and-education/research-support/lucris/about-us - 2026-08-21

use the information you entered to create a neat CV (Curriculum Vitae) in an instant The purpose of this module is to enable quick and simple re-use of data registered in the system for personal customized CVs. On this page you will find how you as a researcher can use the CV module. Why the CV module existsOnce you as a researcher have spent time updating LUCRIS with relevant information about yo

https://www.staff.lu.se/research-and-education/research-support/lucris/use-lucris/creating-cv - 2026-08-21